dornase alfa

CLINICAL USE

To improve pulmonary function in cystic fibrosis

DOSE IN NORMAL RENAL FUNCTION

2.5 mg (2500 u) daily via nebuliser can be increased to twice daily if over 21 years of age

PHARMACOKINETICS

Molecular weight :29 249.6

%Protein binding :No data

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :11 (from lungs in rats)

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Nebulised

Rate of Administration

–

Comments

<15% of dose is systemically absorbed

OTHER INFORMATION

No pharmacokinetic data available; little systemic absorption therefore little accumulation expectedUse undiluted, using recommended jet nebuliser/compressor system.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home